CRBU
Caribou Biosciences Inc
1.20$
-2.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.5% | -5.9% | -8.3% | -7.7% | -9.0% | -12.7% | -19.3% | -11.7% | -7.9% | -17.1% | -4.2% | |
| – | -3.4% | -10.1% | -11.0% | -12.4% | -7.6% | -0.9% | -11.4% | -19.2% | -6.6% | -15.7% | -4.7% | |
| – | -50.8% | -3.4% | -23.3% | -15.6% | -49.0% | +80.5% | -14.3% | -55.8% | +10.9% | -2.5% | +117.3% | |
| – | -2.9% | -10.6% | -11.0% | -12.8% | -8.2% | -0.5% | -11.8% | -19.9% | -5.4% | -15.6% | -4.5% | |
| – | -24.9% | -6.4% | -19.3% | -8.6% | +22.0% | -15.7% | +1.5% | +5.4% | +1.7% | -20.7% | -17.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.7% | -0.4% | -1.7% | +1.1% | -4.4% | -6.5% | -2.9% | -3.0% | +8.1% | -18.2% | -4.9% | |
| – | +15.2% | +2.5% | +6.6% | +3.9% | -4.7% | -7.0% | +1.4% | -2.9% | -9.4% | -22.6% | -8.6% | |
| – | +5.4% | +146.2% | +3.7% | -61.5% | +21.1% | +33.3% | +20.3% | +17.5% | -55.3% | +7.2% | +7.0% | |
| – | +31.3% | +90.4% | -45.7% | -16.2% | -8.4% | +56.4% | -16.3% | +17.3% | +52.0% | -39.4% | -12.1% | |
| – | -7.5% | -6.8% | -9.6% | -9.4% | -10.0% | -14.1% | -23.5% | -14.6% | -13.9% | -16.5% | -3.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.5% | +1.0% | +1.2% | +0.1% | -0.2% | +2.6% | +0.4% | +0.3% | +1.3% | +1.4% | +5.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.